Pro-inflammatory cytokines involvement in the hesperidin antihyperalgesic effects at peripheral and central levels in a neuropathic pain model

2017 ◽  
Vol 25 (2) ◽  
pp. 265-269 ◽  
Author(s):  
A. I. Carballo-Villalobos ◽  
M. E. González-Trujano ◽  
N. Alvarado-Vázquez ◽  
F. J. López-Muñoz
Keyword(s):  
Neuropathic Pain ◽  
Inflammatory Cytokines ◽  
Pain Model ◽  
Neuropathic Pain Model ◽  
Pro Inflammatory Cytokines

scholarly journals The activation of galanin receptor 2 plays an antinociceptive effect in nucleus accumbens of rats with neuropathic pain

2021 ◽  
Vol 71 (1) ◽  
Author(s):  
Yan Dong ◽  
Chong-Yang Li ◽  
Xiao-Min Zhang ◽  
Ya-Nan Liu ◽  
Shuang Yang ◽  
...  
Keyword(s):  
Neuropathic Pain ◽  
Nucleus Accumbens ◽  
Pain Threshold ◽  
Antinociceptive Effect ◽  
Galanin Receptor ◽  
Pain Model ◽  
Withdrawal Threshold ◽  
Neuropathic Pain Model ◽  
Galanin Receptors ◽  
Intact Rats

AbstractOur previous research has shown that galanin plays an antinociceptive effect via binding to galanin receptors (GalRs) in nucleus accumbens (NAc). This study focused on the involvement of GalR2 in galanin-induced antinociceptive effect in NAc of neuropathic pain rats. The chronic constriction injury of sciatic nerve (CCI) was used to mimic neuropathic pain model. The hind paw withdrawal latency (HWL) to thermal stimulation and hind paw withdrawal threshold (HWT) to mechanical stimulation were measured as the indicators of pain threshold. The results showed that 14 and 28 days after CCI, the expression of GalR2 was up-regulated in bilateral NAc of rats, and intra-NAc injection of GalR2 antagonist M871 reversed galanin-induced increases in HWL and HWT of CCI rats. Furthermore, intra-NAc injection of GalR2 agonist M1145 induced increases in HWL and HWT at day 14 and day 28 after CCI, which could also be reversed by M871. Finally, we found that M1145-induced antinociceptive effect in NAc of CCI rats was stronger than that in intact rats. These results imply that the GalR2 is activated in the NAc from day 14 to day 28 after CCI and GalR2 is involved in the galanin-induced antinociceptive effect in NAc of CCI rats.

scholarly journals Pharmacological Evidence on Augmented Antiallodynia Following Systemic Co-Treatment with GlyT-1 and GlyT-2 Inhibitors in Rat Neuropathic Pain Model

2021 ◽  
Vol 22 (5) ◽  
pp. 2479
Author(s):  
Amir Mohammadzadeh ◽  
Péter P. Lakatos ◽  
Mihály Balogh ◽  
Ferenc Zádor ◽  
Dávid Árpád Karádi ◽  
...  
Keyword(s):  
Neuropathic Pain ◽  
Animal Studies ◽  
Acute Administration ◽  
Pain Model ◽  
Therapeutic Value ◽  
Small Doses ◽  
Function Test ◽  
Neuropathic Pain Model ◽  
First Time ◽  
Glycine Content

The limited effect of current medications on neuropathic pain (NP) has initiated large efforts to develop effective treatments. Animal studies showed that glycine transporter (GlyT) inhibitors are promising analgesics in NP, though concerns regarding adverse effects were raised. We aimed to study NFPS and Org-25543, GlyT-1 and GlyT-2 inhibitors, respectively and their combination in rat mononeuropathic pain evoked by partial sciatic nerve ligation. Cerebrospinal fluid (CSF) glycine content was also determined by capillary electrophoresis. Subcutaneous (s.c.) 4 mg/kg NFPS or Org-25543 showed analgesia following acute administration (30–60 min). Small doses of each compound failed to produce antiallodynia up to 180 min after the acute administration. However, NFPS (1 mg/kg) produced antiallodynia after four days of treatment. Co-treatment with subanalgesic doses of NFPS (1 mg/kg) and Org-25543 (2 mg/kg) produced analgesia at 60 min and thereafter meanwhile increased significantly the CSF glycine content. This combination alleviated NP without affecting motor function. Test compounds failed to activate G-proteins in spinal cord. To the best of our knowledge for the first time we demonstrated augmented analgesia by combining GlyT-1 and 2 inhibitors. Increased CSF glycine content supports involvement of glycinergic system. Combining selective GlyT inhibitors or developing non-selective GlyT inhibitors might have therapeutic value in NP.

Characterization of a novel neuropathic pain model in mice

Neuroreport ◽  
2008 ◽  
Vol 19 (8) ◽  
pp. 825-829 ◽  
Author(s):  
Richard Hulse ◽  
David Wynick ◽  
Lucy F. Donaldson
Keyword(s):  
Neuropathic Pain ◽  
Pain Model ◽  
Neuropathic Pain Model

Differential effect of brain-derived neurotrophic factor on high-threshold mechanosensitivity in a rat neuropathic pain model

2000 ◽  
Vol 278 (1-2) ◽  
pp. 85-88 ◽  
Author(s):  
Kenji Miki ◽  
Tetsuo Fukuoka ◽  
Atsushi Tokunaga ◽  
Eiji Kondo ◽  
Yi Dai ◽  
...  
Keyword(s):  
Neuropathic Pain ◽  
Neurotrophic Factor ◽  
Differential Effect ◽  
Brain Derived Neurotrophic Factor ◽  
High Threshold ◽  
Pain Model ◽  
Neuropathic Pain Model

Amorphous solid dispersions of hecogenin acetate using different polymers for enhancement of solubility and improvement of anti-hyperalgesic effect in neuropathic pain model in mice

2018 ◽  
Vol 97 ◽  
pp. 870-879 ◽  
Author(s):  
Carlos Demócedes Luís de França Almeida Moreira ◽  
Jonas Gabriel de Oliveira Pinheiro ◽  
Walter Ferreira da Silva-Júnior ◽  
Euzébio Guimarães Barbosa ◽  
Zênia Maria Maciel Lavra ◽  
...  
Keyword(s):  
Neuropathic Pain ◽  
Solid Dispersions ◽  
Amorphous Solid ◽  
Amorphous Solid Dispersions ◽  
Pain Model ◽  
Neuropathic Pain Model ◽  
Hecogenin Acetate

Cannabis constituent synergy in a mouse neuropathic pain model

Pain ◽  
2017 ◽  
Vol 158 (12) ◽  
pp. 2452-2460 ◽  
Author(s):  
Sherelle L. Casey ◽  
Nicholas Atwal ◽  
Christopher W. Vaughan
Keyword(s):  
Neuropathic Pain ◽  
Pain Model ◽  
Neuropathic Pain Model
Sign in / Sign up

Export Citation Format

Share Document